08 Jan
  • By Greg Freeman
  • Cause in

Italfarmaco – Winter Newsletter 2020

Italfarmaco’s EPIDYS clinical trial for Givinostat is enrolling boys age 6 and up at 40 sites around the world. See the details in Italfarmaco’s Winter 2020 community newsletter. Or join us in Houston, Texas at our CureDuchenne Cares Workshop on February 8, 2020. Two great reasons to sign up for the Workshop: Italfarmaco will be there […]

READ MORE
19 Dec
  • By Greg Freeman
  • Cause in

Mallinckrodt Comments on its BRAVE study

Mallinckrodt Comments on its BRAVE study (A Multicenter, Randomized, Parallel Group, Double Blind, Multiple Dose, Placebo Controlled Study to Assess the Efficacy and Safety of MNK-1411 in Male Subjects 4 to 8 Years of Age With Duchenne Muscular Dystrophy) DECEMBER 19, 2019 -(MALLINCKRODT)- After careful consideration and despite engaging in diligent efforts to research, develop […]

READ MORE
15 Oct
  • By Greg Freeman
  • Cause in

cTAP Publishes Comprehensive Analysis of the North Star Ambulatory Assessment (NSAA), a Newly Adopted Primary Outcome Measure in Clinical Trials of Patients with Duchenne Muscular Dystrophy

CAMBRIDGE, Mass.–(BUSINESS WIRE)–The collaborative Trajectory Analysis Project (cTAP), a multi-stakeholder, global coalition in Duchenne muscular dystrophy (DMD), publishes research in the journal PLOS ONE providing quantitative insights to assist the design and analysis of clinical trials in patients with DMD. The NSAA outcome measures the ability of patients to conduct a variety of activities – […]

READ MORE
27 Mar
  • By CureDuchenne User
  • Cause in

Catabasis Connection – March 2019

In the latest Catabasis Connection, they take us behind-the-scenes with the PolarisDMD experience. Learn what it’s like to participate in their PolarisDMD clinical trial. Read the full newsletter here.

READ MORE